SCHEDULE 13G/A: Rubric Capital Management Discloses 4.56% Stake in Coherus BioSciences

Rubric Capital Management LP and David Rosen have filed an amended Schedule 13G, disclosing a beneficial ownership of 4.56% of Coherus BioSciences, Inc.'s common stock as of December 31, 2024.

Summary

• Rubric Capital Management LP and David Rosen, collectively referred to as the "Reporting Persons," have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Coherus BioSciences, Inc.
• As of December 31, 2024, the Reporting Persons beneficially own an aggregate of 5,258,754 shares of Coherus BioSciences, Inc. common stock.
• This ownership represents 4.56% of the total outstanding common stock of Coherus BioSciences, Inc.
• The percentage is calculated based on 115,213,407 shares of common stock outstanding as of October 31, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q.
• Rubric Capital Management LP is identified as an investment adviser, and David Rosen is the Managing Member of its general partner.
• The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: This is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate a positive or negative sentiment regarding the issuer's performance or outlook.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Disclosure of a significant, though non-controlling, stake by an institutional investor provides transparency regarding the ownership structure of Coherus BioSciences, Inc.

Key Dates

Keywords

Coherus BioSciences, Rubric Capital Management, David Rosen, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Biotechnology, Pharmaceuticals, Healthcare